Anthrax immune globulin Injection

Brand(s)
Anthrasil
Category(s)
other
SPL Type(s)
Plasma Derivative
Master SPL
Cangene Corporation (2015-11-12)
Oldest Current Product
2015-10-05
License(s)
BLA
RxNORM
INJECTION\ANTHRAX IMMUNE GLOBULIN
SPL Active
INTRAVENOUS\LIQUID\ANTHRAX IMMUNE GLOBULIN HUMAN
SPL Moiety
INTRAVENOUS\LIQUID\ANTHRAX IMMUNE GLOBULIN HUMAN

product(s) by strength(s)

anthrax immune globulin, human 60 unt injection

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1604920249AnthrasilBLACangene Corporation2015-10-05ANTHRAX IMMUNE GLOBULIN HUMANINTRAVENOUSLIQUID12556297cc9a89-6fe0-424e-82d1-0cf9d19444db

application(s)

#idtitleapprovedtradenamesfda division
1125562Anthrax Immune GlobulinIntravenous (Human) Application2015-03-24AnthrasilCBER

spl(s)

#idtitlecategorytypelabelerlabeler actlast updateversionproduct(s)
197cc9a89-6fe0-424e-82d1-0cf9d19444db (view SPL)These highlights do not include all the information needed to use ANTHRASIL safely and effectively. See full prescribing information for ANTHRASIL.ANTHRASIL [Anthrax Immune Globulin Intravenous (Human)], sterile solution for infusionInitial U.S. Approval: 2015otherPlasma DerivativeCangene CorporationMANUFACTURE2015-11-121604920249

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII